Cargando…
Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Autores principales: | Pouliquen, I. J., Howarth, P., Austin, D., Gunn, G., Meyer, E., Price, R. G., Bradford, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668989/ https://www.ncbi.nlm.nih.gov/pubmed/29118815 http://dx.doi.org/10.1186/s13223-017-0217-6 |
Ejemplares similares
-
Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Mukherjee, Manali, et al.
Publicado: (2017) -
Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019) -
Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab
por: Pouliquen, Isabelle J., et al.
Publicado: (2015) -
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019) -
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)